These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18632654)

  • 1. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.
    Donev RM; Gray LC; Sivasankar B; Hughes TR; van den Berg CW; Morgan BP
    Cancer Res; 2008 Jul; 68(14):5979-87. PubMed ID: 18632654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms.
    Kolev MV; Ruseva MM; Morgan BP; Donev RM
    J Immunol; 2010 Jun; 184(11):6035-42. PubMed ID: 20421646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.
    Kolev MV; Tediose T; Sivasankar B; Harris CL; Thome J; Morgan BP; Donev RM
    Pharmacogenomics J; 2010 Feb; 10(1):12-9. PubMed ID: 19884909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Am J Pathol; 2000 Mar; 156(3):1085-91. PubMed ID: 10702424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.
    Spiller OB; Criado-García O; Rodríguez De Córdoba S; Morgan BP
    Clin Exp Immunol; 2000 Aug; 121(2):234-41. PubMed ID: 10931136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
    Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
    Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59.
    Donev RM; Cole DS; Sivasankar B; Hughes TR; Morgan BP
    Cancer Res; 2006 Feb; 66(4):2451-8. PubMed ID: 16489052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).
    Maio M; Brasoveanu LI; Coral S; Sigalotti L; Lamaj E; Gasparollo A; Visintin A; Altomonte M; Fonsatti E
    Int J Oncol; 1998 Aug; 13(2):305-18. PubMed ID: 9664126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
    Marx S; Wilken F; Wagner I; Marx M; Troschke-Meurer S; Zumpe M; Bien-Moeller S; Weidemeier M; Baldauf J; Fleck SK; Rauch BH; Schroeder HWS; Lode H; Siebert N
    J Neurooncol; 2020 May; 147(3):577-585. PubMed ID: 32246395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis.
    Li B; Gao MH; Chu XM; Xu YJ; Yang F
    Cell Oncol (Dordr); 2012 Oct; 35(5):355-65. PubMed ID: 22945508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Knocking down human CD59 gene expression decreased protection to complement-mediated cytolysis].
    Shi XX; Gao MH; Li XP; Zhang B; Wang QB
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1164-6. PubMed ID: 19068201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.
    Chen J; Ding P; Li L; Gu H; Zhang X; Zhang L; Wang N; Gan L; Wang Q; Zhang W; Hu W
    Stem Cell Reports; 2017 Jan; 8(1):140-151. PubMed ID: 28017655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
    Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
    J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer.
    Shi XX; Zhang B; Zang JL; Wang GY; Gao MH
    Cell Mol Immunol; 2009 Feb; 6(1):61-6. PubMed ID: 19254481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation.
    Sandomenico A; Ruggiero A; Iaccarino E; Oliver A; Squeglia F; Moreira M; Esposito L; Ruvo M; Berisio R
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins.
    Gasque P; Thomas A; Fontaine M; Morgan BP
    J Neuroimmunol; 1996 May; 66(1-2):29-40. PubMed ID: 8964911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.